Eupraxia Pharmaceuticals Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
EPRX Nasdaq 2834 www.eupraxiapharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders - Jun 19th, 2026 2:02 pm
Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - May 28th, 2026 6:00 am
Eupraxia Pharmaceuticals Q1 Loss Narrows - May 12th, 2026 3:21 pm
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results - May 12th, 2026 3:00 pm
Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week - May 6th, 2026 5:00 am
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW) - May 5th, 2026 5:00 am
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer - May 1st, 2026 3:05 pm
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting - Apr 22nd, 2026 5:00 am
Eupraxia Reports Latest 36-Week Results From Resolve Trial - Apr 21st, 2026 5:32 am
Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis - Apr 21st, 2026 5:00 am
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences - Apr 13th, 2026 6:00 am
New Strong Sell Stocks for April 2nd - Apr 2nd, 2026 4:03 am
Eupraxia Reports Positive Six-Month Data From Eosinophilic Esophagitis Trial - Mar 17th, 2026 5:38 am
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis - Mar 17th, 2026 5:00 am
Eupraxia Pharmaceuticals Q4 Loss Widens - Mar 13th, 2026 5:19 am
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results - Mar 12th, 2026 7:03 pm
Eupraxia Pharmaceuticals Closes US$63.2M Public Offering Including Full Exercise of Underwriter Option - Feb 20th, 2026 1:38 pm
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option - Feb 20th, 2026 1:10 pm
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering - Feb 19th, 2026 5:28 am
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants - Feb 19th, 2026 12:18 am